Csenge Advisory Group LLC recently announced the acquisition of new stake in TC BioPharm (Holdings) plc ADR (NASDAQ:TCBP). This fresh investment now brings its stake to 0.17% valued currently at $4121.0. In addition, Cresset Asset Management LLC raised its holdings by 1250.0 to 1250.0 shares.
With over 0.47 million TC BioPharm (Holdings) plc ADR (TCBP) shares trading Friday and a closing price of $2.55 on the day, the dollar volume was approximately $1.19 million. The shares have shown a negative half year performance of -75.17% and its price on 01/12/24 gained nearly 4.08%.
Shares of TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP) opened at $2.46, up $0.01 from a prior closing price of $2.45. However, the script later moved the day high at 2.8800, up 4.08%. The company’s stock has a 5-day price change of 14.86% and -63.68% over the past three months. TCBP shares are trading -19.56% year to date (YTD), with the 12-month market performance down to -96.81% lower. It has a 12-month low price of $2.03 and touched a high of $192.20 over the same period. TCBP has an average intraday trading volume of 105.80K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.30%, -58.06%, and -79.46% respectively.
Institutional ownership of TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP) shares accounts for 3.22% of the company’s. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $1.73M and a beta (3y monthly) value of 0.11. The earnings-per-share (ttm) stands at -$44.53. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.19% over the week and 23.33% over the month.
Analysts forecast that TC BioPharm (Holdings) plc ADR (TCBP) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2023. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate TC BioPharm (Holdings) plc ADR (TCBP) as a “Strong Buy” at a consensus score of 1.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
